Cancer and neoplasms

ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study (ACTION)

GO TO STUDY

Reproductive health and childbirth

A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (Azalea)

GO TO STUDY

Metabolic and Endocrine

The Oxford BioBank [RENEWAL 2023]

GO TO STUDY

Risk Stratification of Interstitial Lung Abnormalities using Hyperpolarised Xenon MRI and blood biomarkers

GO TO STUDY

MyeloFiT: Myeloproliferative Neoplasms – Imaging-based assessment of Fibrosis and Thrombosis Risk (MyeloFiT)

GO TO STUDY

Oxford Genetic Frontotemporal Dementia Initiative 3 (GENFI)

GO TO STUDY

Cancer and neoplasms

A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ- 88549968, a T-cell Redirecting Bispecific Antibody for CALR mutated Myeloproliferative Neoplasms

GO TO STUDY

Interrogating immune- tumour interactions within the central nervous system

GO TO STUDY

Cancer and neoplasms

Study of HRO761 alone or in combination in cancer patients with specific DNA alterations called Microsatellite Instability - High or Mismatch Repair Deficiency. (HRO761)

GO TO STUDY

A phase 1 study to assess the safety and immunogenicity of R21/Matrix-MTM administered in an escalating dose, multi-prime vaccination schedule in healthy adults (VAC096)

GO TO STUDY